Hepagene 雅创医药




Non-alcoholic Steatohepatitis (NASH)

Chronic Hepatitis B Infection (HBV)


Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

About HPG1860

About NASH

About Hepagene Therapeutics, Inc


Non-alcoholic Steatohepatitis (NASH)
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide, with the prevalence of NAFLD in western countries about 20-30% of their general populations. Among them, 20-25% of NAFLD patients will progress to NASH, marked by steatohepatitis, ballooning and inflammation. Typically, NASH is accompanied with liver fibrosis and can further progress to liver cirrhosis and hepatocellular carcinoma (HCC). NASH is currently ranked the second most common reason for liver transplants in the United States and is expected to become the leading cause for liver transplant by 2020.
We are targeting different pathways contributing to NASH and aim to address the unmet medical needs through combination therapies.
Chronic Hepatitis B Infection (HBV)
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic diseases. Estimated 350-400 million people worldwide are chronically infected with hepatitis B. Among them, 25% suffer from the active disease, while 30-40% are immune-tolerant and 35-45% have inactive disease. HBV is truly a silent killer with more than 1M death every year due to complications of hepatitis B, including cirrhosis and liver cancer.
We are targeting covalently closed circular DNA (cccDNA) and hepatitis B surface antigen (HBsAg) which are essential for HBV functional cure. Treatment based on these novel mechanisms will potentially offer a curative outcome for HBV patients through combination with existing polymerase inhibitors and/or compounds under development.